cに応じられた阻害 | c-Met Inhibition
Effect of Crizotinib on c-MET expression in c-MET altered cancer cells.... | Download Scientific Diagram
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer
Crizotinib (PF-02341066) | ALK/c-Met/ROS1阻害剤 | MedChemExpress
Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology | Future Oncology
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers - Lung Cancer
Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer - Clinical Lung Cancer
Effects of crizotinib on ALK/MET phosphorylation, AKT and ERK... | Download Scientific Diagram
PLOS ONE: Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
Crizotinib in Patients With MET-Amplified NSCLC - Journal of Thoracic Oncology
Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Crizotinib inhibits c-MET activation and shows in-vitro efficacy in CRC... | Download Scientific Diagram
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. | Semantic Scholar
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial - Annals of Oncology
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
Crizotinib-resistant MET mutations in gastric cancer patients are sensitive to type II tyrosine kinase inhibitors | Future Oncology
Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway - eBioMedicine
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation - Clinical Lung Cancer
![Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation [Abstract]](https://www.ijbs.com/v16/p2595/toc.jpg "Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation [Abstract]")
Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation [Abstract]
JCM | Free Full-Text | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer | HTML
MET mutations identified following crizotinib treatment. (A–C) The... | Download Scientific Diagram
Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF - memoinOncology
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
Crizotinib is an Orally Active, ATP-Competitive ALK and c-Met inhibitor - Network of Cancer Research
ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer: Cell Reports
